Long-Acting Release Microspheres Containing Novel GLP-1 Analog as an Antidiabetic System
Authors:
- Sida RuanSRSida Ruan
- Yuanyuan GuYGYuanyuan Gu
- Bo LiuBLBo Liu
- Huashan GaoHGHuashan Gao
- Xiongwei HuXHXiongwei Hu
- Haiping HaoHHHaiping Hao
- Liang JinLJLiang Jin
- Ting CaiTCTing Cai
- 15 May 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (7) , 2857-2869
Abstract
Glucagon-like peptide 1 (GLP-1) has recently received significant attention as an efficacious way to treat diabetes mellitus. However, the short half-life of the peptide limits its clinical application in diabetes. In our previous study, a novel GLP-1 analog (PGLP-1) with a longer half-life was synthesized and evaluated. Herein, we prepared the PGLP-1-loaded poly(d,l-lactide-co-glycolide) microspheres to achieve long-term effects on blood glucose control. The incorporation of zinc ion into the formulation can effectively decrease the initial burst release, and a uniform drug distribution was obtained, in contrast to native PGLP-1 encapsulated microspheres. We demonstrated that the solubility of the drug encapsulated in microspheres played an important role in in vitro release behavior and drug distribution inside the microspheres. The Zn-PGLP-1 microspheres had a prominent acute glucose reduction effect in the healthy mice. A hypoglycemic effect was observed in the streptozotocin (STZ) induced diabetic mice through a 6-week treatment of Zn-PGLP-1-loaded microspheres. Meanwhile, the administration of Zn-PGLP-1 microspheres led to the β-cell protection and stimulation of insulin secretion. The novel GLP-1 analog-loaded sustained microspheres may greatly improve patient compliance along with a desirable safety feature.Keywords
Funding Information
- State Project for Essential Drug Research and Development (No.2017ZX09301075)
This publication has 68 references indexed in Scilit:
- Glucose-Responsive Microgels Integrated with Enzyme Nanocapsules for Closed-Loop Insulin DeliveryACS Nano, 2013
- Injectable Nano-Network for Glucose-Mediated Insulin DeliveryACS Nano, 2013
- Mapping Microclimate pH Distribution inside Protein-Encapsulated PLGA Microspheres Using Confocal Laser Scanning MicroscopyMolecular Pharmaceutics, 2012
- GLP1-derived nonapeptide GLP1(28–36)amide protects pancreatic β-cells from glucolipotoxicityJournal of Endocrinology, 2012
- The mechanisms of drug release in poly(lactic-co-glycolic acid)-based drug delivery systems—A reviewInternational Journal of Pharmaceutics, 2011
- Influence of morphology and drug distribution on the release process of FITC-dextran-loaded microspheres prepared with different types of PLGAJournal of Microencapsulation, 2008
- Glucagon-Like Peptide-1 Gene Therapy in Obese Diabetic Mice Results in Long-Term Cure of Diabetes by Improving Insulin Sensitivity and Reducing Hepatic GluconeogenesisDiabetes, 2007
- Structure and function studies of glucagon‐like peptide‐1 (GLP‐1): the designing of a novel pharmacological agent for the treatment of diabetesDiabetes/Metabolism Research and Reviews, 2005
- Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double-emulsion solvent extraction/evaporation methodBiomaterials, 2001
- Changing the pH of the external aqueous phase may modulate protein entrapment and delivery from poly(lactide-co-glycolide) microspheres prepared by a w/o/w solvent evaporation methodJournal of Microencapsulation, 1998